基于CiteSpace的伊伐布雷定研究热点及前沿趋势可视化分析

打开文本图片集

文献标识码：A

中图分类号：R972

文章编号：1006-1959（2025）18-0013-06

DOI：10.3969/j.issn.1006-1959.2025.18.003

Visual Analysis ofResearch Hotspotsand Frontier Trends ofIvabradine Based on CiteSpace

LANXi1，CHENCongling2³，WUHan1，ZHANGRuobin²³，YANGXian² （1.Department of Cardiology，NanjingDrum TowerHospital，Nanjing21Ooo8，Jiangsu，China; 2.Department of Pharmacy，Nanjing Drum TowerHospital，Nanjing 21ooo8，Jiangsu，China;

3.SchoolofBasic MedicineandClinicalPharmacy，ChinaPharmaceuticalUniversity，Nanjing21198，Jiangsu，China）

Abstract：ObectieTvisualithesearchsulsofiabradinebyusingowledgeapalyeitseseachsatusdtredsdproide referenceforfuturereseachinthisfeldMethodsBbliometrisandCiteSpacevisualanalysissoftwarewereusedtoanalyzeteivabadine literatureincludedineWebfience（WO）databasefroto.ResultsAtotalof316iteraturesereicludd，ndeof lieraturesnivabradieasotsefroOteotyiheargesumbeofblcatiosastUnitedSatestest withthlargestumberofpublicatiosasteUniversityofGlasgo;theuthorwiththeargestumberofpublicatiosasCHELO， withatotalofiteraturesublisd;teosiuthorsSWEDBERGK，ichasied476tie．“eartatesteeyodihte ighestodfrldsdtoeinlalaisioi β blockersdatioapgsttatiotesisolicfucioolicfuctiooddct （bradycardiaceent）ndteustodseentyaserencaelandmehanism.ConcusionIprovingeprogosisofatintsit cardiovasculardseasetogheartateegulationisresearhtsotofivabradineExploringeardiovasularprotetionehanisf ivabradine and new disease treatment targets is the future development trend.

KeyWords：Ivabradine;CiteSpace;Visual analysis;Bibliometrics;Knowledge graph

伊伐布雷定（ivabradine）是首个窦房结起搏If电流选择特异性抑制剂，由法国施维雅公司（Servier）研发，于2005年在欧洲被批准上市治疗稳定性冠心病，于2015年在我国获批上市用于慢性心衰的治疗。（剩余8677字）